Galia Kut

Veteran investor and mentor in early-stage Israeli companies, with a focus on deep tech, AI, big data analysis, and women-led startups.

Angel Investor Active Jerusalem, Israel
Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
total disclosed, rounds participated
Stages

About

Galia Kut is a Jerusalem-based veteran investor and mentor in early-stage companies. She has a strong technical background with degrees in Computer Science and Computational Linguistics/AI from USC and Stanford, respectively, and over 30 years of experience in technical and senior management roles. She invests in and advises early-stage companies, with particular interests in deep tech, artificial intelligence, big data analysis, and women-led startups. She also serves on several boards of directors.

Portfolio

No portfolio companies in this dataset yet.

Investment activity

Portfolio by sector

Health Tech & Life Sciences2

Q&A

What is Galia Kut's primary investment focus by sector?
Galia Kut primarily focuses on the Health Tech & Life Sciences sector, with two investments in this area.
Can you name some of Galia Kut's portfolio companies?
Galia Kut's portfolio includes Mindtension, which is developing a rapid diagnostic platform for ADHD, and Pepticom, focused on novel peptide drug candidates.
What is Galia Kut's typical investment stage?
Galia Kut has participated in both Pre-Seed and Series A funding rounds.
When did Galia Kut make her most recent known investment?
Galia Kut made an investment in July 2021.
What was the funding stage and amount for Pepticom?
Pepticom raised a $14.2M Series A round, in which Galia Kut participated.
What is Mindtension's business model and funding stage?
Mindtension operates on a B2B business model and received Seed funding, with Galia Kut as an investor.
What is the typical investment range for Galia Kut?
Galia Kut's investment range is between $750K and $5M.
When was Galia Kut's earliest known investment?
Galia Kut's earliest known investment occurred in August 2019.